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Abstract 
 
Striated muscle regeneration holds an intrinsic complexity governed by many 
orchestrated events. When the fine balance of regulatory machineries is under strain, the 
homeostatic conditions are lost and degeneration starts to occur. This is the case for 
inherited and acquired diseases of both cardiac and skeletal muscles. A wide range of 
factors is currently under scrutiny for better understanding the details underlying de-/re-
generation processes, of both genetic and non-genetic nature. This review focuses on 
three classes of non-genetic factors regulating striated muscle regeneration, i.e. 
microRNAs, signaling pathways and epigenetic regulators. 
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List of abbreviations 
 
DNMTs  DNA methyltransferases 
Ezh1/2   Enhancer Of Zeste Homolog 1/2   
HGF   Hepatocyte growth factor 
H3K4me3  Trimethylation of lysine 4 on histone 3 
H3K27me3  Trimethylation of lysine 27 on histone 3 
H3K9me2  Dimethylation of lysine 9 on histone 3 
IGF   Insulin growth factor 
IGFR   Insulin growth factor receptor 
IL-6   Interleukin 6 
MAGIC-F1  Met-activating genetically improved  chimeric factor 1 
MDs   Muscular Dystrophies 
MEF2   Myocyte enhancer factor-2 
miRNAs  MicroRNAs  
MLP   Muscle LIM protein 
MRFs   Myogenic regulatory factors 
MyoD   Myogenic differentiation 1 
RISC    Rna-induced silencing complex  
SRF   Serum response factor 
TCF-complex  Trancription factor complex   
UTR   Untranslated region  
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Introduction 
 
During the past years, accumulating evidence in a number of tissues has shed more light 
on the role of non-genetic factors in homeostasis and regeneration of striated muscles, i.e. 
cardiac and skeletal muscles. These unconventional factors are becoming increasingly 
intriguing because of their fine timely tuning on downstream conventional genetic 
factors. Non-genetic factors include short non-coding RNAs, such as microRNAs 
(miRNAs), ligand-triggered signaling cascades and epigenetic factors, such as histone 
remodelers and DNA methyltransferases. This review will therefore concisely report on 
the role of non-genetic factors from those three classes in striated muscle de-/re-
generation.      
 
MiRNAs and muscle regeneration 
 
MiRNAs are short non-coding RNAs that regulate gene expression at post-transcriptional 
level. MiRNAs are encoded in the genome either as individual transcriptional units, or 
often as intergenic clusters of several miRNAs. However, growing evidence has shown 
that a number of miRNAs are enclosed in the intronic sequences of other genes and are 
therefore transcribed along with the coding genes [1, 2]. In the nucleus, miRNAs are 
generally transcribed by RNA polymerase II in primary transcripts called pri-miRs, 
subsequently cleaved by the microprocessor complex into shorter precursor molecules 
called pre-miRs [3]. Pre-miRs are then transported into the cytosol, where they are 
further cleaved in ~22nt-long double-stranded molecules by a complex that includes 
another RNase-III, Dicer. MiRNAs are then ready to be loaded on the RNA-induced 
silencing complex (RISC): the guide strand is loaded while the star strand is generally 
degraded [4].	MiRNAs recognize target sequences at the 3’ untranslated region (3’-UTR) 
and repress target gene expression either by targeting the mRNA for degradation or by 
mediating translation inhibition [5]. 
A number of miRNAs have been characterized as myogenic modulators (Figure 1). 
Along well-characterized miRNAs important for muscle homeostasis, during the last few 
years new studies have pointed out at novel players. MiR-1 and miR-133 are well-
established members of the so-called myomiRNA family and orchestrate skeletal and 
cardiac muscle regeneration [6]. Although encoded from the same loci and transcribed 
together, mir-1 and mir-133 develop into two separate mature miRNAs that hold specific 
functions. Via the regulation of SRF and MEF2, in fact, they establish distinct negative 
feedback loops that intrinsically modulate the cellular proliferation and differentiation 
within muscle cell linages [7]. Mir-206 has also been well characterized as a positive 
regulator of the myogenic commitment, by supporting satellite cell differentiation and 
repressing many negative modulators of skeletal muscle differentiation [8]. Its 
involvement in muscle diseases, for example muscular dystrophies (MDs), has been 
equally identified [9-11]. In several muscle disorders, including MDs, miRNAs levels are 
altered. For instance regenerative miR-31, miR-206, miR-449 are induced in animal 
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models (mdx mouse) and in Duchenne MD patients during the regenerative stage, while 
other miRNAs, such as miR-1 and miR-29c, are down-modulated during fiber 
degeneration. These observations suggest that the regenerative miRNAs boost 
differentiation towards myofibers, while during fiber degeneration other miRNAs 
negatively regulate apoptotic pathway as a compensatory mechanism for myofiber loss 
[12]. Evidence is also accumulating for a set of non-muscle-specific miRNAs that have 
an effect on muscle remodeling by targeting muscle-specific regulatory factors. An 
important difference in contrast to mir-1, mir-133 and mir-206, whose expression is 
muscle specific, is that these miRNAs are broadly expressed in several tissues and yet 
retain muscle-specific functions [13]. An example is miR-181, a broadly expressed 
miRNA that has been shown to contribute to myoblast differentiation by targeting a 
MyoD repressor in mammals [14]. Mir-181 family comprises six different mature 
products that are involved in many biological processes, including vascular development, 
apoptosis, and immunological response among others. For instance, mir-181a increases 
immature T-cell sensitivity and direct positive and negative selection, intrinsically tuning 
T-cell antigen recognition [15]. Furthermore, it has been shown that mir-181 family has a 
role in several cancer types: mir181b is overexpressed in prostate cancer and cervical 
cancer, while mir-181a is upregulated in ovarian and breast cancer [16-18].  
Similarly , mir-24, although not a traditional muscle-specific miRNA, plays a role in 
positively modulating myogenesis via inhibition of members of the TGF-beta family 
[19]. Interestingly, mir-24 is expressed at a later stage of muscle differentiation, 
suggesting an additional important function in the maintenance of the skeletal and cardiac 
muscle homeostasis.  
Along the aforementioned miRNAs, other studies have recently reported the role of 
additional miRNA regulators. In the cardiac muscle, new evidence has emerged that the 
regeneration process is additionally (dys)regulated by miRNAs. Mir-128 has a role in 
cardiac hyperplasia and deposition of extracellular matrix [20]. Moreover, it has been 
attributed with an anti-myogenic role also in the skeletal muscle, as overexpression of 
this miRNA inhibits cell proliferation [21]. In addition, the importance of another cluster 
of miRNAs, the mir-17-92 cluster, has recently emerged. Mir-17-92 cluster is required 
and sufficient to induce cardiomyocyte proliferation, and mir-19a has been pointed out as 
the major player within the cluster [22, 23]. For the skeletal myogenesis, many studies have 
suggested that mir-29 is a positive regulator of myogenesis. This ubiquitous miRNA is 
involved in myogenesis by repressing Polycomb silencing complex genes and thereby 
influencing the chromatin state of early myogenesis genes [24, 25]. Additionally, another 
study has revealed a more direct target of mir-29, namely Akt3, which is a tyrosine kinase 
responsive to growth factor signaling, thus linking miR-29 to myoblast differentiation via 
muscle growth mechanisms [26]. Another remarkable example of fate-driving miRNAs 
consists of miR-669a/q, which normally repress MyoD in murine cardiomyogenic cells. 
Dystrophic cardiomyopathic mice displayed depletion of miR-669a/q levels and aberrant 
commitment of cardiac mesoangioblasts [27]. Also, long-term over-expression of the 
missing miRNA in the myocardium of these mice alleviated end-stage cardiomyopathy 
and increased survival [28]. 
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Thus, unconventional miRNAs are gathering increasingly more attention in achieving 
complex muscle regulation. However, more studies are required in order to enlighten the 
still obscure relationships within the muscle-specific endogenous miRNA circuitries. 
Also, it will be fundamental to elucidate the cellular players potentially involved in 
mediating the muscular phenotypes induced by these miRNAs. 
Recently, several studies have investigated the roles of exosomes in mediating cell-to-cell 
interactions. Interestingly for this review, exosomal communication has been further 
associated with skeletal and cardiac muscle remodeling. Exosomes are extracellular 
vesicles, matured from multivesicular bodies and loaded with a cargo of proteins and 
different types of RNAs, which are then trafficked in the circulation in steady state and 
upon induction [29, 30]. MiRNAs can be carried in the circulation either via exosomes, 
or via non-vesicular carriers, namely protein- or lipoprotein-complexes [31, 32]. 
Regardless of the carrier nature, the circulating miRNAs are definitely gaining 
momentum in the study of long-range signals for muscle regulation [32, 33]. If specific 
miRNAs are enriched in both muscle types and if myocytes shed circulating miRNAs, it 
is expectable to trace muscle-specific miRNAs in serum or plasma upon striated muscle 
injuries. Indeed, mir-1, mir-133 and mir-206 are found in body fluids of animal models 
with skeletal or cardiac degenerative diseases and such observations have further been 
confirmed in patients [34-36]. Furthermore, a few studies have reported that exosomes 
secreted during muscle cell differentiation carry fundamental myomiRNAs, suggesting 
the importance of exosomal miRNAs in orchestrating intracellular communication [37, 
38]. Similarly, paracrine action of exosomes secreted by stem cells has been reported, 
pointing at exosomes as crucial agents in tissue regeneration elicited by cell therapy [39, 
40]. For instance, exosomes produced by mesenchymal stem cells promote skeletal 
muscle repair through activation of angiogenesis and myogenesis pathways [40]. 
Moreover, exosomes secreted by cardiosphere-derived cells have been identified as 
pivotal mediators in improvement and regeneration of the infarcted murine heart [39]. 
Exosome-borne miRNAs are definitely gaining momentum as putative biomarkers, 
prognostic markers and shuttling signals. However, it is important to further investigate 
the causal relationships in the exosome-mediated processes. This will be indeed crucial to 
better discriminate between trafficking exosomes and passively released exosomes in the 
context of striated muscles. 
 
 
Signaling pathways regulating muscle growth 
 
Muscle functions are controlled by signaling pathways that drive muscle response to 
metabolic and physiological changes, and guide regeneration (Figure 1). The muscle per 
se is a metabolic tissue with paracrine properties. Along with hormones and external 
regulatory factors, myokines –i.e. cytokines produced and released from the skeletal 
muscle- contribute to maintaining homeostasis and are also involved in the process of 
myogenesis [41].  Muscle remodeling is a dynamic process occurring throughout the 
whole tissue life span. During development, protein synthesis and progenitor activation 
	 7	
contribute to new muscle formation. Conversely, during adulthood, cellular turnover 
generally decreases and the muscle mass plasticity is mainly determined by the interplay 
between anabolism and catabolism [42]. Muscular atrophy and muscular hypertrophy are 
therefore two processes that intertwine in muscle remodeling [43]. The IGF1/PI3K/Akt 
signaling pathway is involved in muscle hypertrophy in both skeletal and cardiac muscle 
[44, 45]. In particular the Akt/mTOR signaling pathway is upregulated during hypertrophy 
and downregulated during atrophy, indicating its crucial role in maintaining muscle 
homeostasis [44]. Binding of IGF to its receptor IGFR causes a downstream 
phosphorylation cascade, which results in activation of phosphatidylinositol-3-kinase 
PI3K and the subsequent activation of Akt [46]. Equally important for muscle 
hypertrophy is the HGF-Met signaling pathway. Very interestingly, Met, the high affinity 
receptor of HGF, is expressed on satellite cells, amongst other several cell types [47, 48]. 
Transgenic mice expressing a chimeric genetically engineered protein derived from HGF 
(MAGIC-F1) were generated [49, 50]. Such mice constitute a murine hypertrophic model 
and display hypertrophy in the heart and in the skeletal muscle.  
Myostatin is one of the most powerful negative regulators of muscle growth. In skeletal 
muscle, myostatin negatively regulates muscle mass through interference with Akt 
signaling pathways. Recent evidence has shown that, together with myostatin, other 
members of the TGFβ family might be involved in regulating skeletal muscle mass and 
differentiation. In particular, activin-A has been found to be upregulated in skeletal 
muscle after activation of the tumor necrosis factor alpha/TAK-1 signaling pathway [51]. 
Furthermore, in the past few years, new signaling players have been unraveled in muscle 
regeneration. Modulation of G-coupled proteins has been reported to promote skeletal 
muscle hypertrophy and accelerate skeletal muscle regeneration [52, 53]. Additionally, 
interest in the inflammatory pathways involved in muscular disorders has been growing, 
because chronic inflammation is a hallmark of many muscle degenerative conditions, 
including MDs. Interleukin-6 (IL-6) is, for example, an essential regulator of satellite 
cell-mediated hypertrophic muscle growth, as it is transiently produced by myofibers and 
it increases hypertrophic response [54]. Furthermore downstream IL-6, STAT3 signaling 
has been shown to directly control satellite cell expansion and it has been associated with 
repair of the skeletal myofibers [55]. Much less is known on the involvement of the 
aforementioned pathways in cardiac regeneration. TGFβ family proteins have been 
involved in modulating the critical regenerative steps following myocardial infarction and 
have therefore been studied as potential cardiac regeneration modulators [56, 57]. 
Interestingly for heart regeneration, the recently investigated Hippo/Yap pathway has 
been found to play essential roles in the regulation of heart development and postnatal 
cardiomyocyte proliferation through several mechanisms. Yap can interact with different 
pathways, ranging from Wnt pathway, through stimulation via β-catenin and TCF 
complex, to interaction with IGF signaling [45, 58-60]. 	
Notch signaling pathway is a major player in regulating skeletal and cardiac myogenesis, 
and regeneration. Not only is the Notch pathway important during development, but its 
crucial function in maintaining adult somatic stem cells and driving their fate makes it a 
key factor in the study of muscle regeneration [61, 62]. Notch signaling is a conserved 
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pathway that relies on intracellular ligands and receptors exposed by cells in proximal 
physical contact. Conventionally, the major ligands are Dll1/3/4, Jagged1/2 and there are 
four receptors, Notch1-4. Recently, several pieces of evidence have shown the 
involvement of Notch signaling in promoting satellite cell self-renewal and myogenic 
regenerative capacity [63, 64]. Moreover, very recent results have reported the effect of 
Notch signaling on non-satellite resident myogenic stem cells, showing the pivotal role of 
Notch in driving cell fate of murine and human mesoangioblasts [65]. Notch signaling 
plays a predominant role in the cardiac muscle as well, both in the developing heart and 
as a critical determinant of cardiac stem cell proliferation and differentiation [66-68]. 
Quite recently, an in vivo study has reported the importance of the activation of Notch 
signaling pathway after transplantation in order to maintain and ameliorate cell 
engraftment [69]. 
Metabolism- and energy-related signals, both circulating and local, are emerging as 
complex remodelers of the myogenic cell/tissue programs. Ghrelin, for instance, is a 
gastric hormone stimulating growth hormone release and positive energy balance. Both 
forms of circulating ghrelin, acylated and unacylated, have been demonstrated to promote 
myoblast differentiation [70] and to counteract muscle atrophy in mice [71] through p38-
dependent mechanisms, albeit independently from its conventional receptor [72]. 
Skeletal muscle is a highly metabolic and energy-requiring tissue, thus mitochondrial 
function is pivotal in maintaining energy balance and muscle homeostasis. Mitochondrial 
dysfunction can therefore also affect muscle and its regeneration. Mutations that cause 
impairment of mitochondrial fusion results in severe mitochondrial DNA depletion and 
muscle abnormalities, such as atrophy [75]. Mitochondrial myopathies are marked by 
perturbations in mitochondrial biogenesis, content and function, leading to muscle 
weakness and functionality loss. To this regard, studies have reported that exercise 
training might improve muscle function of patients with mitochondrial DNA mutations 
by activation of specific stress signals that act as positive modulators of crucial 
transcriptional pathways implicated in skeletal muscle mitochondrial biogenesis, fusion 
and metabolism [76, 77]. Furthermore, increasing evidence points at dysfunctional 
mitochondria as hubs of impaired signaling based on disrupted energy transfer/sensing. 
An example has been firstly reported in the case of MLP-null transgenic mice, displaying 
regional absence of mitochondria and thereby disturbed energy balance in the 
myocardium, leading to dilated cardiomyopathy [73]. Interestingly, skeletal muscle 
mitochondrial dysfunction has been associated with metabolic diseases, such as type 2 
diabetes, under inactive conditions [74]. 
Therefore, manipulating the signaling pathways still constitutes a fascinating perspective 
for regulating the myogenic paths, often in clinically relevant conditions. However, many 
questions are still open on how the diverse pathways intertwine with each other in cardiac 
and skeletal muscles, and in the different stem cell pools. In this view, it will be 
important to dissect the cellular players and the signal directionalities involved in 
diseased/regenerating striated muscles.  
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Epigenetic regulators: adding up on myogenic complexity 
 
Not only do genetic factors influence cell fate decision and myogenesis in the adult 
skeletal and cardiac muscle, but it is increasingly evident that there is a non-negligible 
level of cooperative regulation carried out by epigenetic mechanisms, transcription 
factors and signaling [78]. Epigenetic factors, such as chromatin remodeling, histone 
mark modifications and DNA methylation, play therefore an important role in regulating 
muscle gene expression. Muscle transcription factors, e.g. MyoD and MEF2, are 
regulated by histone deacetylases in undifferentiated myoblasts to prevent unscheduled 
activation, while upon differentiation such complexes are displaced and histones are 
accessible for activating modifications, i.e. acetylation of H3K27 and trimethylation of 
H3K4 [79-81]. Closely linked to histone mark modification is the DNA methylation 
machinery regulating MyoD. This layer of expression control was firstly observed  when 
treatment with a DNA methyltransferase inhibitor, 5-azacytidine, converted 10T1/2 
embryonic fibroblasts to myoblasts [82]. 
Although not many studies have been performed on quiescent satellite cells, it is 
generally accepted that skeletal muscle satellite cells are kept in quiescent state also by 
means of epigenetic cues, DNA methylation and repressive histone marks [83]. When the 
muscle is injured, satellite cells are activated. In this state, cell cycle genes and early 
myogenic fate markers are characterized by permissive histone marks, whereas 
quiescence markers, such as Pax7, are silenced by repressive marks [83]. Recent 
evidence has reported the presence of poised domains in quiescent satellite cells, where 
chromatin carries bivalent histone marks. Several genes, including important myogenic 
regulatory factors, are marked by permissive histone marks, such as H3K4me3, 
indicating that satellite cells are primed for future myogenic differentiation already at a 
quiescent state by keeping key genes under poised chromatin state [84]. Polycomb groups 
and thritorax groups’ proteins have been largely implicated in the modulation of histone 
status during myogenesis and muscle regeneration [85, 86]. These two histone 
methyltransferase complexes act in opposite ways, as they respectively establish low 
levels and high levels of transcription on the same regulatory genes. In the skeletal 
muscle, Ezh1 and Ezh2, proteins of the polycomb complex, are responsible for epigenetic 
regulation of satellite cells and support of their expansion and early differentiation, but 
are also interestingly required for the homeostasis of the adult satellite cell pool [85, 87, 
88].	 Additionally, as a possible link between chromatin modification and DNA 
methylation, Ezh2 was shown to target the de novo DNA methyltransferase enzymes, 
DNMT3a and DNMT3b, to specific genes [89]. Interestingly, a recent study has shown 
the involvement of Ezh2 and DNMT3b in pathological conditions: in Duchenne MD both 
factors cooperate to achieve repression of the transcription at the Notch 1 promoter 
during satellite cell activation, thus causing repression of the muscular regenerative 
capacity [90]. Intriguingly, novel evidence has reported that several genes involved in 
Notch signaling pathway hold hypomethylated and hydroxymethylated intragenic or 
intergenic regions in myoblasts and myotubes [91]. 
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Not much is known with regards to the epigenetic factors regulating cardiac regeneration. 
It is however established that several cardiovascular diseases are associated with 
epigenetic modifications. Heart failure is reportedly marked by abnormal DNA 
methylation and altered gene expression of angiogenic factors. Conversely, the histone 
acetyltransferases domain of p300, which acetylates transcription factors such as GATA4, 
is involved in promoting LV remodeling after myocardial infarction. This aspect emerges 
from the observation of cardiovascular system abnormality and depressed cardiac dilation 
in transgenic mice overexpressing intact p300 in the heart, but not in mice overexpressing 
a mutant p300, lacking its histone acetyltransferase activity [92, 93]. ATP-dependent 
chromatin remodeling complexes have been implicated in cardiac development and 
function, especially those of the SWI/SNF family. These complexes can remove, add or 
displace nucleosomes using ATP [94]. During the development of the cardiac muscle, 
several epigenetic mechanisms have an important role in timing the expression of 
regulatory cardiac genes. Histone acetyltransferases allow timing of the expression of 
regulatory genes, histone deacetylases have a role in remodeling, while characteristic 
DNA methylation patterns establish regulatory circuits. However, whether these 
developmental regulatory elements can be relevant for cardiac regeneration therapies still 
remains to be elucidated in future studies. 
 
 
Perspectives 
 
In conclusion, the study of unconventional non-genetic factors in myogenesis is 
contributing to deciphering striated muscle complexity, while amassing novel intriguing 
questions. An important question substantially still open is which and how non-genetic 
signals overlap in determining cardiac vs skeletal myogenic routes, particularly in 
humans. Systematic approaches in this perspective, likely with the help of advanced bi-
directional cell systems, will definitely improve our knowledge and handling of the two 
myogenic routes, consolidating previous translational approaches. A second intriguing 
perspective consists in the tantalizing question of where/when the different non-genetic 
cues converge in specifying the myogenic fates. In this context, a shift from anecdotic to 
comprehensive paradigms is needed in order to increase the complexity of interpretation 
for future findings on striated muscle regeneration.    
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Figure 1 – Schematic representation of several non-genetic myogenic modulators 
reported in the review. Ligands and downstream signaling pathways are reported on the 
left, whereas miRNAs, possibly through exosome-mediated trafficking, are listed on the 
right. Arrow-capped connectors represent positive regulation, whereas circle-capped 
connectors indicate complex modulation.     
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